AbbVie reports positive Phase 2 results for zumilokibart

• AbbVie (NYSE:ABBV) reported that all three zumilokibart dose regimens met the primary endpoint in the Phase 2 APEX Part B study.
• The trial showed statistically significant EASI-75 response improvements and skin clearance results compared with placebo in adults with moderate to severe atopic dermatitis.
• AbbVie selected the mid-dose regimen for Phase 3 development after observing stronger skin severity and itch reductions compared with placebo.

AbbVie (NYSE:ABBV) reported positive Phase 2 APEX Part B study results for zumilokibart, with all three tested dose regimens achieving the primary endpoint among 346 adults with moderate to severe atopic dermatitis.

The study evaluated three zumilokibart dose levels against placebo, and AbbVie reported statistically significant improvements in EASI-75 response rates at Week 16 compared with placebo, along with improvements in skin clearance and itch reduction.

The company reported that the mid-dose regimen showed greater reductions in skin severity at Week 1 and itch at Week 2 compared with placebo and was selected by AbbVie for Phase 3 development, while treatment-emergent adverse events occurring in at least 5% of any treatment group included nasopharyngitis, headache, noninfective conjunctivitis, upper respiratory tract infection, atopic dermatitis and urinary tract infection.

AbbVie develops medicines across several therapeutic areas, including immunology, oncology, neuroscience and eye care, with its immunology portfolio including treatments for inflammatory conditions.

The company continues to evaluate new therapies through clinical development programs, with zumilokibart being studied as a potential treatment option for adults with moderate to severe atopic dermatitis.